National Medical Association presents award to Eli Lilly
INDIANAPOLIS An organization representing the nation’s African-American doctors has given drug maker Eli Lilly & Co. an award to recognize the company’s partnership with the organization.
Lilly announced Monday that it had received the National Medical Association’s Corporate Circle Partners award at the NMA’s 113th annual conference and scientific assembly this weekend in Las Vegas.
“We can’t do this alone,” NMA executive director Mohammad Akhter said in a statement. “As strong as the NMA and Lilly are separately, together, we have greater impact in this country for the betterment of all of us.”
Collaborations between the NMA and Lilly have included the Global Health Initiative and the Fearless African-Americans Connected and Empowered campaign, designed to help African-Americans living with diabetes.
NACDS urges House to improve Part D, control prescription drug expenditures in healthcare reform legislation
ALEXANDRIA, Va. Retail pharmacy chains hope to see changes to Medicare Part D and assistance in controlling prescription drug expenditures included in the America’s Affordable Health Choices Act of 2009, according to a letter delivered to members of the House this week.
In the letter – written to House Ways and Means Committee chairman Chuck Rangel, D-N.Y., House Energy and Commerce Committee chairman Henry Waxman, D-Calif., and the committees’ ranking Republicans – National Association of Chain Drug Stores president Steven Anderson praised sections of the bill designed to cover the Medicare Part D coverage gap. The gap, also called the doughnut hole, causes seniors to lose Part D coverage when their annual prescription drug expenditures are between $2,700 and $6,154.
Anderson urged policies including a clarification of language ensuring that pharmacies would not be expected to cover the discounted portion of the price of a drug covered under Part D; expansion of extended days’ supplies of drugs – such as 90-day supplies – as a way to reduce dispensing fees and copays; and a rolling Part D enrollment period to alleviate disruptions in care that he said resulted from current enrollment rules.
Teva settles patent suit with Ortho-McNeil-Janssen
JERUSALEM Teva Pharmaceutical Industries has announced its settlement of its patent infringement lawsuit over its generic version of a popular contraceptive.
Teva said it has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the suit in the U.S. District Court for the District of New Jersey related to Teva’s generic Ortho Tri-Cyclen Lo. Under the terms of the settlement, Teva will obtain a release for past sales of its generic product, in exchange for an undisclosed royalty payment. Teva also will obtain a license to re-enter the market on December 31, 2015, or earlier in certain circumstances.
The settlement will not become effective until the court enters a proposed consent judgment upholding the validity and enforceability of Ortho’s patent.